When efficacy was compared with that of 177Lu-PSMA-I&T, 177Lu-rhPSMA-10.1 significantly reduced tumor growth from days 32 to 49, whereas 177Lu-PSMA-617 significantly reduced tumor growth on day 49 only. Here, FOLH1 is linked to neoplasm.